Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Celltrion

http://

Latest From Celltrion

Celltrion Files Tocilizumab In US

Celltrion has become the latest firm to file for a tocilizumab biosimilar in the US, submitting its CT-P47 candidate to the FDA.

Biosimilars United States

Celltrion Reveals 2030 Ambition Amid 80mg High-Concentration Adalimumab Launch

Celltrion has grand ambitions to grow its portfolio and top line by the start of the next decade, as the firm told the recent Annual J.P. Morgan Healthcare Conference.

Biosimilars Launches

Off-Patent Personnel Moves In 2023 Reflect Growing Interest In Innovator Space

Executive changes at both Viatris and Teva in 2023 saw the companies shift their focus towards the innovator industry. Plus, trade groups saw some significant personnel shakeups, Alvotech expressed hope that new hires would help to resolve manufacturing approval issues, Biocon made changes to its management structure, and more.

Executive Changes Leadership

Bio-Thera Delivers Positive Phase III Results For Stelara Biosimilar

Bio-Thera has announced positive Phase III results for its ustekinumab biosimilar candidate BAT2206, demonstrating that the product is highly similar to originator Stelara in patients with moderate to severe plaque psoriasis. 

Biosimilars Clinical Trials
See All

Company Information

  • Industry
  • Pharmaceuticals
UsernamePublicRestriction

Register